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There are limited data on the relationship between the administered dose of recombinant factor seven (rFVIIa) and
the development of adverse clinical outcomes after congenital heart surgery. This single institution case series reports
on dosing, adverse events, and blood product usage after the administration of rFVIIa in the congenital heart surgery
patient population. A retrospective review identified 16 consecutive pediatric patients at an academic, free-standing,
children’s hospital who received rFVIIa to curtail bleeding following congenital heart surgery between April 2004 and
June 2012. Patients were assessed for survival to hospital discharge versus in-hospital mortality and the presence or
absence of a major neurological event during inpatient hospitalization. The median age at surgery was 6.8 months
(range: 3 days–42 years). Seven patients (44%) survived to hospital discharge and nine patients (56%) died. The cause of
mortality included major neurological events (44%), uncontrolled bleeding (33%), and sepsis (23%). Eight patients
(50%) required extracorporeal membrane oxygenation support following congenital heart surgery. The median
cumulative rFVIIa dose administered was 97 mcg/kg, and the median cumulative amount of blood products
administered was 452 ml/kg. In conclusion, this case series underscores the need to prospectively evaluate the effect
that rFVIIa has on patient survival and the incidence of adverse events, including thrombotic and major neurological
events, in congenital heart surgery patients. Ideally, a randomized, multicenter study would provide the sufficient
numbers of patients and events to test these relationships.
 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
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Abbreviations
rFVIIa recombinant factor seven
CPB cardiopulmonary bypass
CHS congenital heart surgery
ECMO extracorporeal membrane oxygenation
TF tissue factor
MNE major neurological events
RACHS risk adjustment for congenital heart surgery
FFP fresh frozen plasma
PRBC packed red blood cells
ACT activated clotting time
IHM in-hospital mortality
CPBT cardiopulmonary bypass time
CCT cross clamp time
CAT circulatory arrest time
PT prothrombin time
PTT partial thromboplastin time
INR international normalized ratio
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SEVEN USE FOR BLEEDING AFTER CONGENITAL HEART SURGERYIntroduction
The repair of complex congenital heart defectsin children and adults using cardiopulmo-
nary bypass (CPB) can be associated with a high
risk of severe coagulopathy and hemorrhage [1].
The multifactorial causes of these morbidities
include hemodilution, systemic inflammatory
response, and immature coagulation/platelet sys-
tems in neonates [2]. Limited therapeutic options
are available to treat severe bleeding once a surgi-
cally correctable etiology has been ruled out.
Recombinant factor seven (rFVIIa, NovoSeven
RT; Novo Nordisk, Princeton, NJ) was introduced
in the 1980s to treat or prevent bleeding in
patients with hemophilia or factor VII deficiency
[3]. Although labeled to be used for its hemostatic
effects directly at the site of endothelial injury,
rFVIIa has been utilized off-label as a general
hemostatic agent in patients with intractable hem-
orrhage following congenital heart surgery (CHS)
[4]. It has also been used as an off-label drug for
bleeding following trauma, surgery, and extracor-
poreal membrane oxygenation (ECMO) support.
Activated factor VIIa initiates hemostasis by the
formation of a complex with tissue factor (TF), a
transmembrane protein that is released as a result
of blood vessel or tissue injury. The TF-FVIIa com-
plex activates factor X, which then induces throm-
bin formation from pro-thrombin. Thrombin
generation is amplified by the interaction of plate-
lets and factors V, VII, and IX with factor Xa.
Thrombin is crucial for the formation of a stable
fibrin plug that is resistant to premature fibrinoly-
sis. In addition, rFVIIa promotes platelet function
independent of TF activation [5].
Intervention with a potent pro-coagulant com-
pound such as rFVIIa has the potential to restore
hemostasis in patients with intractable hemor-
rhage [6,7]. It also has the potential to cause limb
ischemia, as well as significant pathologic throm-
bosis and related major neurological events
(MNE) leading to death [8]. This report serves as
a single center case series to evaluate cumulative
rFVIIa doses, transfusion requirements, and out-
comes following use in CHS patients.Patients and methods
We reviewed the medical records of patients
without inherent factor deficiencies who received
rFVIIa to limit hemorrhage following CHS at Chil-
dren’s National Health System in Washington,
DC between April 2004 and June 2012. The data
recorded were: age, weight, sex, type of cardiac
defect, type of operation, risk adjustment for con-genital heart surgery (RACHS) score, CPB time,
aortic cross clamp time, rFVIIa dose(s), and type
and amount of blood product transfusion. A total
of 16 consecutive CHS patients who received
rFVIIa either intra or postoperatively met the
inclusion criteria for this series. The patients were
grouped based on in-hospital mortality and the
occurrence of MNE. A major neurological event
was defined as a severe thrombosis-related neuro-
logic complication, which was confirmed by com-
puted tomography, magnetic resonance, or
ultrasound imaging studies.
The operative CPB circuit utilized for all patients
was primed by Plasmalyte A (Baxter, Deerfield, IL)
with the addition of up to one unit of fresh frozen
plasma (FFP) and packed red blood cells (PRBC)
(depending on the blood volume of the patient)
to obtain a hematocrit of 30% at initiation of
CPB. Anticoagulation was achieved with an initial
bolus of 2 mg/kg of heparin in patients below
30 kg and 3 mg/kg in patients above 30 kg. The
adequacy of heparin administration was assessed
by activated clotting time (ACT), and supplemen-
tal heparin was administered when needed to
maintain an ACT above 480 s during extracorporal
circulation. Cardiopulmonary bypass was estab-
lished using a roller pump (Century Heart Lung
Machine, Salyer PRN Biomedical, St. Louis, MO)
and a Terumo CapioxFX05 oxygenator with inte-
gral arterial filter (Terumo Corporation, Tokyo,
Japan). During CPB, pH stat CO2 management
was utilized, and the hematocrit level was main-
tained around 30% with the use of a hemoconcen-
trator (Hemocor HPH, Minntech, Minneapolis,
MN) or by using PRBCs. The use of deep hypo-
thermia and reduced flow bypass varied accord-
ing to the procedure performed. After CPB,
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of 1.3 times the initial heparinization dose in mg.
Additional protamine doses were given to achieve
an ACT below 120 s or lower than preoperative
levels.
For patients requiring postoperative ECMO
support, heparin reversal with protamine was
not performed, and ACT levels were kept between
180 and 220 s with heparin infusion. In all patients,
prothrombin time (PT)/partial thromboplastin
time (PTT)/international normalized ratio (INR)
as well as hematocrit and platelet counts were
checked frequently to determine the need for
blood product administration.Results
For the 16 patients in the study, the demograph-
ics, type of surgery, and operative variables are
summarized in Table 1. Median age at surgery
was 6.8 months (range: 3 days–42 years). Six
patients (38%) underwent single ventricle surgical
palliation while the remaining ten patients (62%)
had biventricular surgical repair. Seven patients
(44%) survived to hospital discharge and nine
(56%) died. The causes of mortality included
MNE (n = 4, 44%), uncontrolled bleeding (n = 3,
33%), and sepsis (n = 2, 23%). Eight patients
received rFVIIa intraoperatively while the remain-
ing eight patients received rFVIIa postoperatively.
The median cumulative rFVIIa dose administered
was 97 mcg/kg (interquartile range, IQR: 89–Table 1. Characteristics and outcomes of the study cohort.
Pt Sex Age Surgery type Weight
(kg)
C
r
f
1b F 21D Biventricular Repair 2.3 1
2 M 3D Single Ventricle Palliation 2.3 1
3b M 11D Biventricular Repair 2.5
4a,b F 13D Biventricular Repair 2.6
5 F 14D Biventricular Repair 2.7
6b F 13D Single Ventricle Palliation 2.9
7b M 12D Single Ventricle Palliation 3.0
8 M 7M, 17D Biventricular Repair 7.0
9 F 6M Single Ventricle Palliation 7.0 1
10a,b M 2Y, 10M, 18D Biventricular Repair 9.1 3
11b F 3Y, 2M, 30D Biventricular Repair 10.0 1
12 F 10Y, 7M, 2D Biventricular Repair 27.0 2
13 M 31Y, 8M, 20D Biventricular Repair 51.0 2
14 F 41Y, 2M,11D Biventricular Repair 52.8
15a,b M 22Y, 4M, 8D Single Ventricle Palliation 55.0 2
16a,b M 36Y, 11M,15D Single Ventricle Palliation 82.0
RACHS, risk adjustment for congenital heart surgery; IHM, in-hospital m
pulmonary bypass time; CCT, cross clamp time; CAT, circulatory arrest tim
a Major neurological event.
b In-hospital mortality.262 mcg/kg). The median cumulative amount of
blood products administered was 452 ml/kg
(IQR: 190–807 mcg/kg). Fifty percent (8/16) of
patients required ECMO support following CHS.
Of these patients, 25% (2/8) survived to hospital
discharge.
Major neurological events and in-hospital mor-
tality are shown in Table 2. Compared to non-
MNE patients, the MNE patients received a larger
cumulative dose of rFVIIa (314 mcg/kg versus
94 mcg/kg) and a larger amount of cumulative
blood products. Four of 16 patients who experi-
enced MNEs died. The cause of death in two of
these four patients was bilateral carotid artery
thrombosis following rFVIIa administration. Both
patients required ECMO support. When compar-
ing survival to hospital discharge and in-hospital
mortality (Table 2), the cumulative rFVIIa dose
and amount of cumulative blood products were
more uniform. However, a higher percentage of
patients with in-hospital mortality received rFVIIa
postoperatively.Discussion
The first off-label use of rFVIIa as a rescue treat-
ment for intractable postoperative bleeding was
reported in 2001 [9]. In our center, the first off-
label use of rFVIIa occurred in 2004 when pub-
lished data regarding the use and dosing of rFVIIa
in neonates and infants after cardiac surgery were
scarce. As more data have become available,umulative
ecombinant
actor VIIa (mcg/kg)
RACHS
score
ECMO CPBT
(min)
CCT
(min)
CAT
(min)
00 3 Y 62 – –
78 6 N 158 – 39
88 6 N 131 – 45
94 2 Y 150 32 32
50 2 N 118 67 –
93 2 Y 75 – 46
60 3 Y – – –
93 2 Y 133 – –
43 2 N 84 49 –
56 4 Y 261 6 9
00 4 Y 189 103 –
53 3 Y 224 104 –
65 2 N 218 33 –
95 3 N 216 67 –
73 3 N 255 – 4
49 3 N 175 – –
ortality; ECMO, extracorporeal membrane oxygenation; CPBT, cardio-
e.
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Table 2. Comparison of variables according to presence or absence of a major neurological event and between survivors and in-
hospital non-survivors.
Variable No MNE (n = 12) MNE (n = 4) Survivors (n = 7) Non-Survivors (n = 9)
Age, d 3 (1–107) 154 (9–405) 8 (1–386) 1 (0–155)
Weight, kg 5.0 (2.6–22.8) 32.1 (4.2–75.3) 7.0 (2.7–51.0) 3.0 (2.5–32.5)
RACHS score 3 (2–6) 3 (2–4) 2 (2–6) 3 (2–6)
Male gender 5 (42%) 3 (75%) 3 (43%) 5 (56%)
Single ventricle 5 (42%) 2 (50%) 2 (71%) 5 (56%)
ECMO 6 (50%) 2 (50%) 2 (29%) 6 (67%)
Cumulative products
rFVIIa, mcg/kg 93.9 (87.8–169.0) 314.4 (138.6–491.5) 142.9 (92.9–253.0) 93.8 (87.9–314.4)
PRBC, ml/kg 277.6 (135.8–400.5) 493.2 (63.8–1272.8) 223.3 (66.6–350.4) 354.3 (124.2–1144.0)
FFP, ml/kg 52.5 (27.8–122.9) 177.4 (29.7–309.0) 44.6 (28.8–148.9) 68.5 (18.8–199.4)
Platelets, ml/kg 47.2 (21.3–95.8) 106.6 (12.8–258.4) 43.9 (16.4–70.4) 96.8 (22.6–202.6)
Cryoprecipitate, ml/kg 5.7 (2.2–11.6) 19.1 (2.0–37.9) 4.3 (2.3–8.6) 10.3 (1.9–34.9)
Postoperative rFVIIa 4 (33%) 4 (100%) 1 (14%) 7 (78%)
Continuous data are median (interquartile range); RACHS score, median (full range).
J Saudi Heart Assoc
2015;27:18–22
KURKLUOGLU ET AL 21
SINGLE CENTER EXPERIENCE ON DOSING AND ADVERSE EVENTS OF RECOMBINANT FACTOR
SEVEN USE FOR BLEEDING AFTER CONGENITAL HEART SURGERYconcerns have increased at our institution and
elsewhere about proper rFVIIa dosing and the
potentially higher risk of thrombotic MNEs, since
MNEs are known complications in the cardiac sur-
gery literature [10].
The standard bolus dosing of rFVIIa for hemo-
philia is 90 mcg/kg administered via intravenous
bolus infusion every two hours until cessation of
bleeding is noted [3]. This pharmacological dosing
strategy is based on rFVIIa’s mechanism of action
to control bleeding that includes both a TF-depen-
dent process and the generation of factor Xa and
IXa on the surface of activated platelets unrelated
to TF. The dosing frequency is every two hours as
the drug half-life is 2.9 h in adults [11].
There is no clear consensus on the appropriate
therapeutic dose of rFVIIa to address postopera-
tive bleeding. In a study including non-cardiac
postoperative patients, Friederich et al. utilized
rFVIIa dosing of 20 mcg/kg and demonstrated that
it was effective [12]. In another study involving
postoperative CHS patients, Karsies et al. noted
that 62% of patients responded to one dose and
29% responded to two doses of rFVIIa with an
amount of 43 ± 22.9 mcg/kg per dose [8]. The
authors concluded that administering 30–50 mcg/
kg per dose every two to four hours would be
effective. In our study, the median cumulative
dose of rFVIIa utilized was 97 mcg/kg. In part, this
stems from nearly half of our patient cohort
undergoing rFVIIa administration while on
ECMO support, wherein much less is known
regarding therapeutic dosing.
The appropriate dosing regimen becomes more
complex when considering patients who are on
ECMO support following cardiac surgery. The
pro-coagulant nature of rFVIIa in the context ofexposure to non-endothelialized surfaces during
ECMO support likely results in activation of circu-
lating platelets [5]. In addition, studies have dem-
onstrated that monocytes retrieved from
oxygenators of CPB systems express TF [6]. Taken
together, both serve as templates for rFVIIa-initi-
ated thrombin generation, leading to ECMO circuit
clotting and possible disseminated intravascular
coagulation following rFVIIa administration
[5,13]. In our case series, 50% (2/4) of patients who
sustained MNEs were on ECMO support, and
75% (6/8) of patients on ECMO support expired.
The 25% observed rate of MNEs was higher than
the rate of adverse thromboembolic events
reported in other studies [14,15]. In our cohort,
two of the four MNE patients who died experi-
enced acute bilateral carotid artery thrombosis fol-
lowing rFVIIa administration. Although
thromboembolic events have been well-described
as complications of treatment with rFVIIa
[10,14,16,17], acute bilateral carotid artery throm-
bosis is uncommon in the published literature
[18,19]. Only one case of acute bilateral carotid
artery thrombosis in a cardiac surgery patient fol-
lowing rFVIIa use has been reported [20]. In our
series, bilateral carotid artery thrombosis was
diagnosed with the use of head computed tomog-
raphy scanning and head ultrasound imaging
with Doppler.
This case series does have several limitations.
Due to its retrospective design, unmeasured con-
founding factors may have contributed to the clin-
ical outcomes that were observed. In addition,
even though this is solely a descriptive case series,
as the sample size is small and the results are from
a single institution, the observed outcomes may
not be applicable to other clinical settings.
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This case series highlights the need for a pro-
spective, multi-center trial with an adequate num-
ber of patients to sufficiently power the study to
further delineate the relationship between rFVIIa
doses and adverse clinical outcomes following
rFVIIa use for bleeding after CHS.Disclosure/funding statement
The authors did not receive any financial sup-
port for the study and declare that they have no
conflict of interest.Institutional review board (IRB) approval
This study was approved by the Institutional
Review Board (IRB) of Children’s National Health
System in Washington, DC, United States.Study limitations
Due to its retrospective design, unmeasured
confounding factors may have contributed to the
clinical outcomes that were observed in this study.
In addition, even though this is solely a descrip-
tive case series, as the sample size is small and
the results are from a single institution, the
observed outcomes may not be applicable to other
clinical settings.Study recommendation
This case series highlights the need for a pro-
spective, multi-center trial with an adequate num-
ber of patients to sufficiently power the study to
further delineate the relationship between rFVIIa
doses and adverse clinical outcomes following
rFVIIa use for bleeding after congenital heart
surgery.
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